Compass Therapeutics Cash Flow Statement
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.6882+0.0097 (+1.43%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Compass Therapeutics free cash flow
In fiscal 2025, Compass Therapeutics generated -$49.1 million of operating cash flow and spent $25,000 on capital expenditures. That left free cash flow of -$49.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Compass Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20202020-03-31 | FY 20192019-12-31 | FY 20192019-03-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M | -29.50M | -37.48K | -34.74M | -36.04K |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 276.00K | 589.00K | 699.00K | 782.00K | 600.00K | 2.40M | — | 2.10M | — |
| Stock-Based Compensation | 8.37M | 8.56M | 6.12M | 5.33M | 4.03M | 4.02M | — | 915.00K | — |
| Change in Working Capital | 9.55M | -2.92M | -1.71M | -161.00K | 7.36M | -3.31M | 5.38K | -157.00K | 3.28K |
| Operating Cash Flow | -49.14M | -44.85M | -40.62M | -34.13M | -19.67M | -26.80M | -32.11K | -31.74M | -32.76K |
| Capital Expenditures | -25.00K | -44.00K | -30.00K | -212.00K | -1.57M | -106.00K | — | -466.00K | — |
| Investing Cash Flow | -93.31M | 46.77M | 26.96M | -151.20M | -1.77M | 38.00K | — | -466.00K | — |
| Debt Repaid | — | — | — | 0 | -9.38M | -5.63M | — | — | — |
| Financing Cash Flow | 129.61M | 17.34M | 2.94M | 75.76M | 118.61M | 48.54M | 30.98K | — | 37.63K |
| Net Change in Cash | -12.84M | 19.25M | -10.72M | -109.57M | 97.17M | 21.77M | -1.12K | -32.21M | 4.87K |
| Free Cash Flow | -49.17M | -44.90M | -40.65M | -34.34M | -21.23M | -26.91M | -32.11K | -32.21M | -32.76K |
This table shows 9 annual periods of Compass Therapeutics's cash flow statement, from FY 2025 back to FY 2019, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CMPX's reporting calendar. What is a cash flow statement?